The QualityStocks Daily Wednesday, May 11th, 2022

Today's Top 3 Investment Newsletters

QualityStocks(AFI) $0.4900 +237.00%

SmallCapRelations(GMGI) $4.2500 +23.91%

MarketClub Analysis(HRB) $28.4100 +19.52%

The QualityStocks Daily Stock List

AnPac Bio-Medical Science (ANPC)

QualityStocks, ChineseWire, InvestorBrandNetwork, MissionIR, BioMedWire, NetworkNewsWire, SeriousTraders, SmallCapRelations, Stocks to Buy Now, Tip.us, StockMarketWatch, StocksToBuyNow, MarketClub Analysis, StreetInsider, BUYINS.NET and PCG Advisory reported earlier on AnPac Bio-Medical Science (ANPC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) is a biotechnology firm that is focused on the research, development, marketing and sale of multi-cancer detection and screening tests to life insurance firms and corporations in China.

The firm has its headquarters in Lishui, the People’s Republic of China and was incorporated in 2010 by He Yu and Chris Chang Yu. The firm operates in the health care sector, under the health care facilities and Svcs sub-industry and manages one clinical lab in the U.S. and two more in China.

The company is led by globally renowned and award-winning nanotechnology and biomedical scientists, engineering experts and medical professionals who are involved in the creation and launch of the company’s cutting-edge, breath-through, early cancer detection, screening and diagnostic technology. The company provides physical checkup package services and cancer differentiation analysis devices.

The enterprise’s CDA program (Cancer Differentiation Analysis), is a proprietary innovative cancer-detection device which measures blood biopsies and helps to dramatically and effectively enhance cancer detection specificity and sensitivity without inducing any side-effects in patients. To date, the CDA program has shown and confirmed more than 22,000 cases, helping to detect and identify early signs of threatening cancers, the cancer type and where it is found in an individual’s body long before the threat can progress and grow into tumors.

The company was recently awarded a disease treatment patent by the U.S. Patent and Trademark Office, which covers new medical devices for both disease treatment and detection applications. This is in addition to launching a cancer treatment joint venture which will finance the development of cancer treatment medical devices. These moves will not only boost the company’s growth and encourage investments into the firm, but also help patients suffering from cancer, if successful.

AnPac Bio-Medical Science (ANPC), closed Wednesday's trading session at $0.3, up 16.4144%, on 1,932,341 volume. The average volume for the last 3 months is 1.932M and the stock's 52-week low/high is $0.2025/$5.66.

Armstrong Flooring (AFI)

InvestorPlace, MarketBeat, StockMarketWatch, Zacks, Marketbeat.com, Trades Of The Day, Market Intelligence Center Alert, StreetInsider, Daily Trade Alert, The Online Investor, QualityStocks, The Street, TradersPro, Trading Concepts, Kiplinger Today, Wealth Insider Alert and StocksEarning reported earlier on Armstrong Flooring (AFI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Armstrong Flooring Inc. (NYSE: AFI) (FRA: 2AS) is focused on designing, manufacturing, sourcing and selling resilient flooring products.

The firm has its headquarters in Lancaster, Pennsylvania and was incorporated in 1860. It serves consumers across the globe, with a focus on the Pacific Rim and North America and has fifteen companies in its corporate family.

The company responsibly and safely operates 7 manufacturing facilities across the globe and works to provide the highest levels of innovation, quality and services. It operates through the Wood flooring and Resilient flooring segments. The former segment is involved in the provision of branded hardwood flooring products that include the Bruce and Armstrong brands, which are used in residential renovations and construction, as well as in commercial applications in offices, restaurants and stores. On the other hand, the latter segment is engaged in designing, manufacturing, sourcing and selling floor coverings, which are mainly used in commercial and home buildings, under the Armstrong brand. The majority of the company’s revenue is derived from the United States.

The enterprise’s products are used in the renovation and construction of institutional, residential and commercial buildings. It sells its products to homeowners, property management firms, installers, contractors, builders, retailers and independent wholesale flooring distributors.

The firm recently reported its financial results for the second quarter of 2021, which show an increase in top line growth. Its CEO noted that they were focused on transforming the company into a more resilient business for its shareholders, employees and customers, which would have a positive effect on the company’s growth, as well as bring investments into the firm.

Armstrong Flooring (AFI), closed Wednesday's trading session at $0.49, up 237.0014%, on 151,852,343 volume. The average volume for the last 3 months is 147.915M and the stock's 52-week low/high is $0.1337/$6.62.

Regis Corporation (RGS)

Streetwise Reports, Daily Markets, MarketBeat, StreetInsider, Zacks, Marketbeat.com, Market Intelligence Center Alert, InvestorPlace, SmarTrend Newsletters, DrStockPick, StockMarketWatch, The Online Investor, RedChip, CRWEPicks, CRWEFinance, Investor Guide, BUYINS.NET, BestOtc, CRWEWallStreet, PennyOmega, Barchart, QualityStocks, Zeke Truligio, SmartMoneyTrading, Stock Tips Network, StockHotTips, Street Insider, SystemTrading, The Motley Fool, Trades Of The Day, Trading Concepts and PennyToBuck reported earlier on Regis Corporation (RGS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Regis Corporation (NYSE: RGS) (FRA: RGI) is a franchisor, operator and owner of hair care and hairstyling salons around the globe.

The firm has its headquarters in Minneapolis, Minnesota and was incorporated in 1922 by Florence Kunin and Paul Kunin. It serves consumers around the globe, with a focus on Puerto Rico, Canada and the United States.

The company operates through the company-owned and franchise salon segments. It operates and franchises salons in 6 divisions, namely International, SmartStyle family hair salons, Trade Secret, MasterCuts, Strip center salons and Regis salons. Most of the company’s salons can be found in Wal-Mart stores, shopping centers and strip malls. Its salons mainly operate under the following trade names: First Choice Haircutters, Roosters, Cost Cutters, Open salon, Sassoon Saloon and Regis Salons. It derives the majority of its revenue from these locations.

The enterprise’s salons offer hair coloring, haircutting and styling services which include shampooing and conditioning. It also sells hair care and beauty products. Brands in the enterprise’s retail assortment include Moroccanoil, Kenra, Regis sexy hair concepts, Paul Mitchell and Biolage. It also provides an OpenSalon mobile app and a back-office salon management system known as OpenSalon Pro. In addition to this, the enterprise operates accredited cosmetology schools. It maintains ownership interests in the MY Style concepts in Japan and Empire Education Group in the United States.

The company recently announced its latest financial results, with its CEO noting that the firm was focused on increasing sales and driving its growth. Its growth will help encourage more investments into the firm.

Regis Corporation (RGS), closed Wednesday's trading session at $0.8901, up 20.1052%, on 1,824,577 volume. The average volume for the last 3 months is 1.806M and the stock's 52-week low/high is $0.74/$10.78.

Charge Enterprises (CRGE)

QualityStocks, Wall Street Grand, 24-7 Stock Alert, Whitehotstocks, Stockhunter.us, Penny Stock Explosion, Open Water Investments, Super Stock Investor, Street Insider, MicroStockProfit, Real Pennies, Stock Preacher, HotOTC, Green Energy Stocks, Global Equity Report, Dubai Penny Stocks, CoolPennyStocks, AnotherWinningTrade, Beacon Equity Research, Topgun stockpicks, Stock Rich, InvestorPlace, Monster Stock Alerts, Bull in Advantage, BullRally, Lebed.biz, Gold and Energy Advisor, Investor Ideas, Investment House, Free Hot Penny Stocks, Market FN, Stock Research Newsletter, Whisper from Wall Street, Traders Content, Trader Central, Top Secret Stocks, TooNiceStocks, The Stock Psycho, The Best Newsletters, Stockpalooza, PROFIT CONFIDENTIAL, StockEgg, OTCReporter, Stock Marketing Inc., SmallCapNetwork, Sling-Shot-Stocks, SeriousTraders, Richard Atlas, PubCo Journal, Penny PayDay, Penny Invest and stockmarketinginc reported earlier on Charge Enterprises (CRGE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Charge Enterprises Inc. (NASDAQ: CRGE) is engaged in the provision of solutions in the electric vehicle charging and wireless network infrastructure installation, including small cell, distributed antennae systems, tower, 5G and electrical infrastructure.

The firm has its headquarters in New York, the United States and was incorporated in 2003, on May 8th. Prior to its name change in January 2021, the firm was known as TransWorld Holdings Inc. It operates as part of the technology sector. The firm serves consumers in the United States.

The company is focused on connecting individuals everywhere using a strategy in telecom network infrastructure, electric vehicle charging infrastructure installation and maintenance and connected calls. It operates through the Infrastructure and the Telecommunications segments. The Infrastructure segment is focused on physical wireless networking elements, including in-building applications, small cell, cell tower, 5G and 4G and EVC solutions. This includes the designing, engineering, construction, installation and maintenance of electric vehicle chargers. This segment also provides a network of personal charging power banks in sporting arenas, transit hubs, restaurants and bars. On the other hand, the Telecommunications segment provides time-division multiplexing access and internet-protocol-based access for domestic switching and associated peripheral equipment services; and long-distance data and voice minutes. It also offers carrier-grade switches and routers for circuit-based and internet services, as well as connection of data and voice call services.

The enterprise was recently approved for uplisting to the Nasdaq Global Market. This approval opens up the enterprise to growth opportunities as well as numerous investments, which will bolster its growth significantly.

Charge Enterprises (CRGE), closed Wednesday's trading session at $3.65, up 22.0736%, on 3,681,168 volume. The average volume for the last 3 months is 3.681M and the stock's 52-week low/high is $2.51/$8.46.

Cue Biopharma (CUE)

MarketBeat, Vantage Wire, StreetInsider, The Online Investor and StockMarketWatch reported earlier on Cue Biopharma (CUE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cue Biopharma Inc. (NASDAQ: CUE) (FRA: 1UC) is a clinical-stage biopharmaceutical firm that is focused on the development of biologic drugs for the selective modulation of the immune system, for the treatment of various autoimmune disorders, chronic infectious illnesses and cancers.

The firm has its headquarters in Cambridge, Massachusetts and was incorporated in 2014, on December 31st by Rodolfo Chaparro, Steven Almo and Ronald D. Seidel III. Prior to its name change in October 2016, the firm was known as Imagen Biopharma Inc. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers in the United States, with a focus on the state of Massachusetts.

The company is party to collaboration agreements with the Albert Einstein College of Medicine and LG Chem Life Sciences, which involves developing Immuno-STATs focused on oncology. It is also party to an agreement with Merck Sharp & Dohme Corp, entailing the research and development of its biologics which target a number of autoimmune diseases.

The enterprise’s product pipeline comprises of CUE-400 and CUE-300 frameworks, which target autoimmune illnesses; and a fusion protein biologic dubbed CUE-101, which is undergoing phase Ib trials in HPV-driven cancers. It also develops a fusion protein biologic dubbed CUE-102, which activates certain T cells to fight cancer; and the CUE-103 Immuno-STATS, which targets pancreatic cancer, lung cancer and colorectal carcinoma.

The company remains focused on addressing high unmet needs in patients with a wide range of solid tumors and hematologic malignancies using its products. Helping patients in need using its formulations will not only benefit the patients but also bring in additional revenue and investments into the company.

Cue Biopharma (CUE), closed Wednesday's trading session at $3.57, off by 15%, on 1,259,579 volume. The average volume for the last 3 months is 1.26M and the stock's 52-week low/high is $3.30/$18.42.

Cortexyme Inc. (CRTX)

Wall Street Resources, MarketBeat, Greenbackers, The Sandman, SmarTrend Newsletters, BUYINS.NET, Schaeffer's, Penny Sleuth, TradersPro, TipRanks, Street Insider and StockMarketWatch reported earlier on Cortexyme Inc. (CRTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cortexyme Inc. (NASDAQ: CRTX) is a clinical-stage biopharmaceutical firm that is engaged in the development of diagnostics and therapeutics for degenerative illnesses like Alzheimer’s disease.

The firm has its headquarters in South San Francisco, California and was incorporated in 2012, on June 20th by Kristen Gafric, Stephen Dominy and Casey Crawford Lynch. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm has two companies in its corporate family and serves consumers in the United States, with a focus on consumers in the state of California.

The company operates through one reportable segment, which is the development and commercialization of therapeutics. Its approach is based on the discovery of the presence of P. gingivalis or Porphyromonas gingivalis and gingipains, which are its secreted toxic factor proteases. These pathogens are tied to beta-amyloid production and neurodegeneration.

The enterprise’s pipeline comprises of an orally administered brain penetrating small molecule gingipain inhibitor dubbed COR388 (atuzaginstate), its lead candidate. This candidate is undergoing phase 2 clinical trials evaluating its effectiveness in treating mild to moderate Alzheimer’s disease. It is also undergoing trials testing its efficacy in treating coronavirus infections and periodontitis, as well as oral squamous cell carcinoma.

The company’s current objectives include advancing its gingipain inhibitor pipeline, expanding upon and supporting clinical evidence of COR388’s mechanism of action. The success and approval of this formulation will bring in additional revenues and investments into the company and bolster its growth.

Cortexyme Inc. (CRTX), closed Wednesday's trading session at $3.14, off by 15.5914%, on 522,378 volume. The average volume for the last 3 months is 520,468 and the stock's 52-week low/high is $3.03/$121.98.

Eargo Inc. (EAR)

Vantage Wire, StreetInsider, Stock Stars, SmallCapVoice, QualityStocks and MarketBeat reported earlier on Eargo Inc. (EAR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Eargo Inc. (NASDAQ: EAR) is a medical device firm that is focused on the development and sale of hearing aids to assist individuals with hearing loss.

The firm has its headquarters in San Jose, California and was incorporated in 2010, on November 12th by Daniel Shen, Raphael Michel and Florent Michel. Prior to its name change in November 2014, the firm was known as Aria Innovations Inc. It operates as part of the medical devices industry, under the healthcare sector. The firm serves consumers in the United States, with a focus on those in the state of California.

The company’s aim is to change the way the world thinks about hearing loss, through the improvement of consumer experience in every step of the hearing care journey. It develops hearing loss solutions which combine knowledge from their on-demand licensed hearing professionals, its proprietary technology and advanced personalized applications to provide high-quality performance.

The enterprise provides hearing aids and professional support services, among other insurance-related services. Its product portfolio includes Eargo Max, Eargo Neo, Eargo Neo HiFi and associated accessories. Its hearing aids enable users to cycle through 4 sound profiles, including features like noise levels and amplifications. The Eargo Neo and Neo HiFi provide a companion mobile application which enables consumers to personalize their sound profiles and control their device.

The firm remains focused on operating its business and future growth opportunities which will bring in more investors into the firm and create value for its stakeholders.

Eargo Inc. (EAR), closed Wednesday's trading session at $1.7, off by 3.4091%, on 735,122 volume. The average volume for the last 3 months is 735,122 and the stock's 52-week low/high is $1.67/$40.21.

Gritstone Bio (GRTS)

StreetInsider, MarketClub Analysis, MarketBeat, BUYINS.NET, TradersPro, QualityStocks and StockMarketWatch reported earlier on Gritstone Bio (GRTS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Gritstone Bio Inc. (NASDAQ: GRTS) (FRA: 2JQ) is a clinical-stage biotechnology firm that is focused on the development of immunotherapies against infectious illnesses and a range of cancers.

The firm has its headquarters in Emeryville, California and was incorporated in August 2015 by Jean-Charles Soria, Naiyer Rizvi, Graham Lord, Mark Cobbold, Timothy Chan and Andrew Allen. Prior to its name change in May 2021, the firm was known as Gristone Oncology Inc. It operates as part of the scientific research and development services industry, under the healthcare sector. The firm has three companies in its corporate family and serves consumers in the United States.

The company is party to a license agreement with Genevant Sciences GmbH. It is also party to a strategic collaboration agreement with Bluebird Bio Inc.; and a collaboration agreement with Gilead Sciences Inc. It markets its products in the U.S.

The enterprise’s products include an immunotherapy candidate dubbed Slate, developed to treat common solid tumors which include pancreatic cancer, colorectal cancer, metastatic non-small cell lung cancer and shared neoantigen-positive tumors. It also develops a neoantigen-based immunotherapy known as Granite, to treat solid tumors comprising colorectal cancer, bladder and micro-satellite stable cancer, gastroesophageal cancer and metastatic non-small cell lung cancer. This is in addition to developing a therapeutic vaccine candidate to protect against SARS-CoV-2 variants; and another to treat and cure HIV infection.

The company is focused on pursuing additional viral pathogens on its vaccine platform and demonstrating the value it brings to patients and stakeholders, which will positively influence the company’s investments as well as its growth.

Gritstone Bio (GRTS), closed Wednesday's trading session at $2.12, off by 7.0175%, on 1,382,265 volume. The average volume for the last 3 months is 1.381M and the stock's 52-week low/high is $2.11/$14.42.

Immunic Inc. (IMUX)

StockMarketWatch, MarketBeat, TradersPro, StreetInsider, BUYINS.NET, QualityStocks and InvestorPlace reported earlier on Immunic Inc. (IMUX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Immunic Inc. (NASDAQ: IMUX) (FRA: 10VA) is a clinical-stage biopharmaceutical firm that is focused on the development of a pipeline of selective oral immunology therapies for treating chronic autoimmune and inflammatory illnesses.

The firm has its headquarters in New York, the United States. Prior to its name change, the firm was known as Vital Therapies Inc. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe, with a focus on the U.S.

The company is focused on research and development activities for oral immunology therapies for the treatment of autoimmune and inflammatory illnesses like psoriasis, ulcerative colitis, relapsing-remitting multiple sclerosis and Crohn’s disease.

The enterprise’s products include IMU-856, IMU-935 and IMU-838. The IMU-935 formulation is an inverse agonist of RORγt; while IMU-838 is a selective immune modulators program that is undergoing phase II clinical trials testing its effectiveness in treating inflammatory bowel disease, relapsing-remitting multiple sclerosis, the coronavirus illness and other chronic autoimmune and inflammatory illnesses. IMU-838 works by blocking the DHODH enzyme. On the other hand, IMU-856 has been developed to restore intestinal barrier function in patients with illnesses like irritable bowel syndrome with diarrhea, inflammatory bowel disease and immune checkpoint inhibitor induced colitis, among other intestinal barrier function illnesses.

The firm, which recently announced its latest financial results, remains focused on strengthening and expanding its intellectual property portfolio. This will help encourage more investments into the firm and help create shareholder value, which will in turn, bolster the firm’s growth significantly.

Immunic Inc. (IMUX), closed Wednesday's trading session at $5.24, off by 4.7273%, on 265,224 volume. The average volume for the last 3 months is 265,100 and the stock's 52-week low/high is $5.11/$15.12.

Vision Hydrogen Corporation (VIHD)

We reported earlier on Vision Hydrogen Corporation (VIHD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Vision Hydrogen (OTCQB: VIHD) today announced that it has monetized its 100% interest in its Vlissingen green hydrogen development project and its 50% interest in its Terneuzen green hydrogen development project through the sale of its Dutch interests to Volt Energy BV (“purchaser”), wholly-owned by its former co-CEO Andre Jurres. According to the update, the purchaser paid total consideration of US$23,627,274, consisting of US$11,250,000 in cash and 1,768,182 shares of the company’s common stock owned by the purchaser, valued at the current market price of $7.00 per share, reducing the company’s outstanding common shares by 8.3% to 19,548,776. “Consistent with our plan to fund our development trajectory through monetizing early-stage development projects, VisionH2 is pleased to have established proof of concept with our initial two projects,” said Andrew Hromyk, Vision Hydrogen CEO. “With numerous hydrogen and carbon abatement projects in very early stages of development across Europe and our proven method economically rewarded much earlier than forecast, the company is well positioned for future growth.”

To view the full press release, visit https://ibn.fm/kL2AS

About Vision Hydrogen Corporation

VisionH2 is a renewable energy company developing clean hydrogen production facilities for the commercial, industrial and transportation sectors. VisionH2 is leveraging its proven track record in site procurement and permitting, accelerating pre-development and grid integration to produce low-carbon and green hydrogen. By establishing and negotiating long-life power supply commitments, the company ensures reliable offtake relationships with industry participants seeking to utilize hydrogen as fuel, feedstock, and as a grid balancing and capacitance solution. VisionH2 is committed to providing the lowest carbon solution with the highest yield hydrogen production, storage and distribution services for the European renewable economy and supply chain. VisionH2 is a portfolio company of First Finance (www.FirstFinance.com), a private equity investment group with offices in Zurich, London and Vancouver. For more information about the company, visit www.VisionH2.com.

Vision Hydrogen Corporation (VIHD), closed Wednesday's trading session at $7.8, up 11.4286%, on 658 volume. The average volume for the last 3 months is 658 and the stock's 52-week low/high is $5.00/$25.00.

Hecla Mining Company (HL)

MarketClub Analysis, SmarTrend Newsletters, InvestorPlace, Schaeffer's, Wyatt Investment Research, Lebed.biz, StocksEarning, MarketBeat, Top Pros' Top Picks, TopStockAnalysts, StreetAuthority Daily, INO.com Market Report, The Street, Money Morning, Zacks, Marketbeat.com, Jason Bond, Kiplinger Today, Daily Trade Alert, Today's Financial News, StreetInsider, Wall Street Grand, TheStockAdvisors, Streetwise Reports, Trades Of The Day, StockOodles, Gryphon Digest, TradersPro, The Wealth Report, QualityStocks, Penny Detectives, National Inflation Association, SureMoney, TradingAuthority Daily, Stockhouse, Darwin Investing Network, ChartAdvisor, Options Elite, PennyStockLive, INO Market Report, Wall Street Daily, Penny Sleuth, Profit Confidential, ProfitableTrading, TraderPower, The Growth Stock Wire, Daily Markets, Greenbackers, Forbes, DrStockPick, Wealth Insider Alert, TradingMarkets, WealthMakers, Investopedia, CustomerService, CRWEWallStreet, CRWEPicks, CRWEFinance, Weiss Research, BestOtc, Barchart, Daily Wealth, MarketArmor.com, AllPennyStocks, PennyToBuck, MonsterStocksPicks, Residual Income Report, Money and Markets, Rockwell Trading, Investing Futures, Stock Stars, Traders For Cash Flow, StockHotTips, Trade of the Week, InvestorGuide, Investor Update, Investor Guide, Investing Lab, PennyOmega and SmallCapVoice reported earlier on Hecla Mining Company (HL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Researchers have developed a new annealing technique that can maintain silver and gold’s structure when these metals are combined in alloys. Annealing is the process of heating a glass or metal and allowing it to slowly cool in an effort to toughen it and remove internal stresses.

Silver, gold, aluminum and copper are elements used in manufacturing optical components due to their reflective properties. For instance, silver and gold are known to reflect blue light and red light respectively.

For the study, the team of researchers, which was led by Olivier Martin, focused on the development of a low-temperature annealing technique that would be effective for an alloy mixture made up of any metals. The researchers started by heating both silver and gold to 300o C for eight hours before increasing the temperature to 450o C for half an hour. This led to the production of an alloyed film of gold-silver, which could reflect the full spectral range.

In the paper, the researchers stated that their findings would be useful in manufacturing holographic optical elements and contact lenses, among other optical components.

Martin added in a media statement that the researchers discovered that they could combine the optical effects of silver and gold into one material by manufacturing an alloy of the two metals. He noted that these metals were relevant to researchers who studied them at the nanoscale, as nanostructures possess an optical response that was different from those of bulky materials. At the nanoscale, light doesn’t interact the same way it would with the same metal in a bigger quantity.

However, conducting research on the nanostructures of these metals isn’t easy because conventional silver and gold alloys are forged at temperatures between 800o C and 1000o C. These high temperatures usually alter the nanostructure form of these metals.

The new annealing technique the researchers developed showed that it could maintain the structure of silver and gold in alloys. This is different from current annealing techniques, which don’t maintain the structure of these metals. The study’s coauthor, Jeonghyeon Kim, stated that the low-temperature technique helped produce well-alloyed materials.

The scientists also investigated different alloy ratios, observing that the optical effects changed as they added more silver or gold to the mixture. Martin believes that the technique could be used in more everyday applications, noting that it may be used in clock-and-watch dials.

The study’s findings were reported in the “Advanced Materials” journal. It was carried out by scientists at the Ecole Polytechnique Federale de Lausanne in Switzerland.

As more applications for different precious metals emerge, precious metals extraction companies such as Hecla Mining Company (NYSE: HL) are sure to keep delivering value to their shareholders well into the future.

Hecla Mining Company (HL), closed Wednesday's trading session at $4.32, off by 0.917431%, on 9,596,327 volume. The average volume for the last 3 months is 9.498M and the stock's 52-week low/high is $4.275/$9.44.

NIO Inc. (NIO)

Green Car Stocks, InvestorPlace, Schaeffer's, The Street, MarketBeat, MarketClub Analysis, Daily Trade Alert, Trades Of The Day, Kiplinger Today, The Online Investor, StocksEarning, StreetInsider, Zacks, StockMarketWatch, BUYINS.NET, QualityStocks, Cabot Wealth, INO Market Report, Wealth Insider Alert, CNBC Breaking News, InvestorsUnderground, The Wealth Report, Investopedia, Early Bird, Daily Wealth, wyatt research newsletter, TradersPro, Energy and Capital, InvestorsObserver Team, CRWEWallStreet, InvestorIntel, MarketClub, Investors Alley, Jim Cramer, AllPennyStocks, TopPennyStockMovers, Top Pros' Top Picks, Stock Market Watch and Wealth Daily reported earlier on NIO Inc. (NIO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

German automaker Volkswagen has revealed that it has sold all the electric vehicles that it plans to sell this year in Europe and the United States. This means that anyone who wants to order an electric vehicle made by a VW brand will have to be patient until next year before their order can be delivered.

Herbert Diess, the Group CEO of VW, revealed that in total, the company’s brands of Porsche, Audi, Skoda and Volkswagen had a combined backlog of 300,000 orders that were yet to be fulfilled in Western Europe. Add to this the orders from the rest of the world, and it becomes clear that the company has plenty of work to do to supply all the vehicles needed by clients from major markets around the world.

Diess added that the company’s order book is huge, and new orders are pouring in thick and fast. This was the reason why the company decided to announce that it had sold out of full -electric vehicles in the American and European markets. The company’s orders in China are also piling up fast, and it is just a matter of time before the order limit for this year is also reached in that market.

It should be noted that VW delivered a total of 99,000 electric vehicles globally in the first three months of this year. In comparison, Tesla tripled that number as its deliveries stood at 310,048 electric vehicles delivered to clients around the world.

It isn’t surprising that Volkswagen is saying it has sold out of electric vehicles in two of the top three EV markets in the world. Data from the European Automobile Manufacturers’ Association indicates that battery EVs almost doubled their share of the market within the European region during the first quarter of this year. Fully electric vehicles claimed a 10% share of all the vehicles sold in Europe in the first three months of this year, while hybrid electric vehicles took 8.9% of the sales registered.

While vehicles powered by fossil fuel registered a decline in their market share, they still took a huge chunk of the sales made in January to March, claiming a 52.8% share of all the vehicles sold in that first quarter.

It is important for electric vehicle makers such as NIO Inc. (NYSE: NIO) to ramp up their production so that motorists who are eager to buy an EV aren’t frustrated by the lengthy wait times before their purchase can be delivered. Otherwise, enthusiasm could wane and push back the timelines within which electrification should have happened on our roads.

NIO Inc. (NIO), closed Wednesday's trading session at $12.71, off by 5.4315%, on 86,326,364 volume. The average volume for the last 3 months is 85.135M and the stock's 52-week low/high is $12.64/$55.13.

The QualityStocks Company Corner

Golden Matrix Group Inc. (NASDAQ: GMGI)

The QualityStocks Daily Newsletter would like to spotlight Golden Matrix Group Inc. (NASDAQ: GMGI).

NetworkNewsWire Editorial Coverage: Luck is a huge aspect of gambling, but luck has a way of favoring the intelligent and showing its back to the foolish. Good online gamblers look for opportunities to improve their odds, then press when probabilities are in their favor. Luck is a fickle mistress and good gamblers know that luck is what happens when preparation meets opportunity. The seduction of gambling dates as early as 200 BC and now flourishes on PCs and mobile devices around the world. Eclipsing $70 billion last year, major casinos and new gaming platforms are fighting for a piece of the action. The market is booming, but there’s a serious drawback for these platforms. Customer acquisition cost for an online casino in the United States is more than $500, and some estimates peg player value at $300 or less. That’s not a winning formula, and many online casino operators now realize that traditional advertising for sports betting and iGaming products presents an irrational cost of customer acquisition. With the online gaming market expected to balloon to more than $130 billion in the next five years, there may be a smarter way to cash in on the action. Providing B2B services such as online gaming platforms, systems, and gaming content has proved to be a winning business model. Coming off its 14th consecutive quarter of profitability, Golden Matrix Group Inc. (NASDAQ: GMGI) is capturing enviable market share delivering state-of-the-art configurable and scalable white label B2B gaming platforms for its customers across the globe. Golden Matrix’s gaming IP includes sophisticated tools for marketing, acquisition, retention, and monetization of users, exactly what platform operators need to achieve profitability. Golden Matrix has established itself as one of the world’s leading providers of turnkey and white label gaming platforms, gaming content, and Esports technology. Others in the sector, such as DraftKings Inc. (NASDAQ: DKNG)International Game Technology (NYSE: IGT)Bragg Gaming Group Inc. (NASDAQ: BRAG) and GAN Limited (NASDAQ: GAN), are also working to expand into new markets and increase shareholder equity.

Golden Matrix Group Inc. (NASDAQ: GMGI), based in Las Vegas, Nevada, is an established gaming technology company that develops and owns online gaming IP and builds turnkey online casino solutions for gaming operators as well as configurable and scalable white-label gaming platforms for international customers, located primarily in the Asia-Pacific region. GMGI’s gaming IP includes tools for marketing, acquisition, retention and monetization of users. The company’s platform can be accessed through both desktop and mobile applications.

GMGI’s sophisticated software automatically declines any gaming or redemption requests from within the United States, in strict compliance with U.S. law.

Golden Matrix, through a subsidiary, also runs a pay-to-enter prize competition in the United Kingdom and Ireland.

The company’s shares began trading on the Nasdaq under the symbol ‘GMGI’ on March 17, 2022. Golden Matrix shares were previously traded on the OTCQX Best Market.

For the quarter ended January 31, 2022, the company reported revenue of $8.88 million, an increase of 355% over the same quarter one year earlier. Net income for the three-month period was $349,379, up from $52,158 a year earlier. It was the company’s 14th consecutive profitable quarter.

In December 2021, Golden Matrix announced it had entered into a purchase agreement to acquire a controlling ownership interest in UK-based RKingsCompetitions Ltd., one of Ireland’s and the United Kingdom’s leading independent online competition companies. RKings presents customers with paid and free entry routes to competitions that offer a range of prizes, including residential properties, luxury and exotic motor vehicles, holiday packages, technology packages and cash. The competitions are currently open only to residents of Ireland and the United Kingdom. Golden Matrix acquired an 80% ownership interest in RKings for cash and stock. The company also secured an option to purchase the remaining 20 percent interest of RKings, subject to certain requirements.

In March 2022, Golden Matrix announced it had applied for a Mexican gaming permit and, once approved, expects to offer online gaming in Mexico as well as roll out the RKings tournament business globally.

Technology

Golden Matrix Group develops fully operational online casino turnkey solutions as well as highly modular, configurable and scalable gaming platforms for its international customers in an effort to promote user acquisition, engagement, retention and monetization. The provided white label gaming platform is unparalleled in both mobile and desktop website deployment, proving compatible throughout all major operating systems and web browsers. In addition, the platform enhances the client’s ability to cater to various gaming scenarios including but not limited to transaction management and a range of loyalty and reward programs. Moreover, user engagement is optimized through the ability to accommodate both free and paid games.

The company’s GM-X System (and recently its next generation GM-Ag System) is considered the industry standard, granting access to over 10,000 games from more than 25 game providers. Through the GM-X System, Golden Matrix offers the industry’s most extensive game portfolio. The company’s gaming partners dominate the global online gaming market to deliver innovative games and premium brand titles. The GM-X System offers payment gateways that integrate with third party platforms or digital wallets. It supports all major currencies and offers multiple language options. The system’s data analytics provide the operator with a 360-degree view of the gaming platform’s performance.

GMGI currently supports over 500 unique casino brands and over 6 million players.

Market Outlook

Online gaming and sports betting sites and apps are increasingly taking market share from traditional location-based casinos. Widespread internet service availability and increasing use of mobile phones for playing online games from homes and public places is driving the market, according to a report from Grand View Research. In addition, factors such as easy access to online gambling, legalization and cultural approval, corporate sponsorships, and celebrity endorsements are also contributing to market growth. The growing availability of cost-effective mobile applications across the globe is further expected to fuel market growth.

This trend is only expected to accelerate as millennials reach their peak earning years and Gen Z youth begin to complete their education and move into careers. These generations are completely comfortable with online recreation, and with using technology like digital wallets and digital gameplay that underpins online gaming.

The global online gambling market was valued at $53.7 billion in 2019 and is expected to grow at a CAGR of 11.5% from 2020 to 2027 to reach a value of $127.3 billion, according to Grand View Research, with much of the growth expected from the U.S. and Asia. Even Europe, the most mature gaming market, is expected to grow at a rate of 20-25% year-over-year.

Management Team

Brian Goodman is CEO of Golden Matrix Group. He has more than 20 years of diverse senior management experience and business development roles within the technology and internet gaming industries. He has a tertiary science qualification as well as a marketing and sales background. His previous roles have been entrepreneurial and include CEO and senior management positions in smaller organizations, which he founded or in which he held equity, as well as multinational organizations.

Cathy Feng is COO at Golden Matrix. She is a co-founder of GMGI and holds a Master of Commerce degree. She has 10 years of experience as a financial officer in the technology and internet gaming industries. In past management positions, she interpreted, analyzed and presented financial and operation information to facilitate business decisions, grow companies and resolve complex problems. In addition, she has skills in marketing, business development, leadership and strategic planning.

Omar Jimenez is CFO and Chief Compliance Officer at GMGI. Prior to joining the company, he was CFO and COO of Alfadan Inc., a supplier of marine outboard engines. He has held senior financial management and operational positions at public and private companies including NextPlay Technologies, American Leisure Holdings, US Installation Group and Onyx Group. He holds various accounting professional certifications, including CPA and CPCU, and degrees in finance, accounting and business.

Henry Zhang is Chief Technology Officer at Golden Matrix. He oversees all aspects of development, integration and deployment of GMGI’s technology systems. He plays a key role in evolving GMGI’s technology business to lead and shape the industry. He is responsible for developing and scaling new businesses, including online gaming, eSport and P2P Systems. He was instrumental in launching the GM-X system and has been with the company for more than six years.

Golden Matrix Group Inc. (NASDAQ: GMGI), closed Wednesday's trading session at $4.25, up 23.9067%, on 104,216 volume. The average volume for the last 3 months is 102,901 and the stock's 52-week low/high is $3.29/$13.10.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

The number of Democratic and Republican senators showing their support for including marijuana banking in the COMPETES Act is growing, and this suggests that not all is lost in regards to enacting a marijuana policy reform this year. It should be noted that the marijuana banking bill was left out of the Senate version of the Innovation & Competitiveness Bill approved by the Senate, but it was included in the version passed by the House of Representatives. A bicameral conference has been established to work on the language of the final text, which will be forwarded to the desk of the president for enactment. Support is growing to include marijuana banking in that final text. It remains to be seen whether the spate of violent robberies targeting cannabis shops will impress upon the conferees the urgent need to allow marijuana firms to have access to banking services. Once that banking is permitted, it will create a trickle-down effect that extends to entities that don’t touch the plant directly but are enablers of the industry in one way or the other, such as Advanced Container Technologies Inc. (OTC: ACTX).

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Wednesday's trading session at $0.995, up 11.6096%, on 209 volume. The average volume for the last 3 months is 209 and the stock's 52-week low/high is $0.66/$4.55.

Recent News

Silo Pharma Inc. (OTCQB: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILO).

Ketamine shows promise in treating Alzheimer’s Disease, Parkinson’s Disease as well as depression, suicide ideation and more. In 2021, Silo Pharma (OTCQB: SILO) entered into a joint venture with Zylö Therapeutics to “explore the clinical development of ketamine using ZTI’s Z-pod (transdermal) technology.” This innovative technology allows Silo, an early-stage biopharmaceutical company, to develop a ketamine delivery system for those suffering dysphagia, a difficulty or complete inability to swallow.(1) Silo Pharma is exploring the efficacy of ketamine in treating patients suffering from both Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”). Over 80% of PD patients(2) and 75% of AD patients(3) experience dysphagia.

Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.

Research

Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (OTCQB: SILO), closed Wednesday's trading session at $0.15, even for the day, on 45,556 volume. The average volume for the last 3 months is 45,556 and the stock's 52-week low/high is $0.12/$0.31.

Recent News

Nowigence Inc.

The QualityStocks Daily Newsletter would like to spotlight Nowigence Inc.

Nowigence was named as one of the finalists in the KPMG Private Enterprise’s Global Tech Innovator competition, which was designed to identify innovators in the United States that have the potential to become the next tech titans on the global stage. The contest recognized companies that show “deep insight” into new market fundamentals, and KPMG Private Enterprise noted that 10 finalists were invited to deliver their final pitches to a panel of industry experts. “Nowigence Inc. was one of those companies. Nowigence is emerging in the AI software space as a top innovative contender with its proprietary offering, Pluaris. The comprehensive, ready-to-use AI platform works around the clock to read and analyze relevant content as it is released in various public and private data sources. Topics can be customized by users,” a recent article reads. “Pluaris opens relevant files stored in tools and databases with which it is integrated. It uses machine learning (‘ML’) and natural language processing (‘NLP’) techniques to analyze the content. This data is then transformed, linked, taxonomized and optimized for storage, analysis, synthesis and retrieval.” To view the full article, visit https://ibn.fm/QW7yc

Nowigence Inc. is a fast-growing SaaS (Software-as-a-Service) company that develops and sells a ready-to-use artificial intelligence (AI) platform called Pluaris™ that automates reading and analysis of textual data. Individuals, teams, and enterprises can now quickly distill knowledge buried in narrative-intensive documents instantaneously from various data sources, both public and private.

Pluaris is created for those who want to read more in less time. It is a Personal Knowledge Management (PKM) tool that generates an annotated data feed based on your topics of interest and automatically creates a permanent personal knowledge base from your feed and private uploads. It has human-like capabilities for comprehending textual data. It summarizes, provides precise answers to questions asked, analyzes different data perspectives, discovers new connections, creates organized nested notes, and allows teams to work collaboratively by sharing in real-time from anywhere in the world to draw informed conclusions.

By integrating state-of-the-art data processing techniques in an intuitive interface at an affordable subscription price, Nowigence puts the power of data science in the hands of consumers. It helps individuals, teams, and organizations to quickly build expertise on one or multiple topics by generating a trove of critical information.

Nowigence targets two user types that rely heavily on fast and accurate research as primary adopters of the Pluaris platform. The first is knowledge workers of all kinds – anyone whose job is to “think for a living” like marketing professionals, researchers, legal professionals, academics, journalists, editors, scientists, and other professionals. The second are individual users who are life-long learners, hobbyists, and enthusiasts of all stripes.

Rather than spending time reading information to gain knowledge from one source at a time, users of Pluaris can gain knowledge from hundreds or thousands of sources in seconds. Keyword-based search-and-retrieval applications don’t open documents, nor read their content, nor extract key points, conduct cause and effect analysis or answer questions specifically. Pluaris includes all those features and goes one step further, with its semantic capabilities to empower users with interpretations of retrieved information. Nowigence estimates this feature alone can save typical researchers between one and three hours per workday. The platform also reduces “noise” by extracting only important and relevant information on every topic being monitored or researched. This helps cut down on information overload, a major source of workplace stress.

Pluaris Builds Intelligence

The Problem

In the modern world, virtually everyone needs to consume a tremendous amount of text-based information, in both our personal and professional lives, but doing so is exceptionally challenging because of:

  • Information Overload: For virtually any significant topic of interest, the amount of textual information available and continually generated is vastly more than can be consumed by an individual.
  • Pervasive Distractions: Thanks to modern technology, we are constantly bombarded with new inputs (e-mails, instant messages, social media, and more) reducing our attention span, leading all too often to TL;DR (Too Long, Didn’t Read).
  • Highly Imperfect Human Recall: The information that we do find time to read is easily forgotten. Even if we retain some of the key insights, the details are almost certainly lost.

Even when working in teams, we often end up researching the same content as our colleagues, and too much of the information acquired by one individual is lost in translation with the communication process to others.

Pluaris

Nowigence has worked with stalwarts and pioneers in the fields of Machine Learning (ML) and Natural Language Processing (NLP) from its early days. The company was keen to solve the big problem of the information age – too much data exists and cannot be processed manually.

Pluaris is designed to be used by regular people from day one with no need for extensive training. The platform is used across different functions and sectors, adapting to clients’ ever-changing needs. Its state-of-the-art no code editing gives organizations the flexibility to improve and tailor their results without hiring data scientists, and real time information retrieval ensures the client never misses any piece of intelligence.

Pluaris adapts to the unique needs by which individuals absorb knowledge. It doesn’t impose structured or rigid methodology. Real time operation means that Pluaris will deliver outputs instantaneously with a click.

A Nowigence team of experts spent three years training Pluaris to understand the context of every sentence it reads. If Pluaris does make an error in contextual interpretation, the user can correct it, which will instantly give the correction precedence over the ML’s algorithmic outputs. This takes away the biggest criticism against AI/ML platforms, that annotating (labeling) data and developing training datasets to build models takes too much time and effort from internal teams.

Use Cases

I need to stay on top of the latest news for my industry. Pluaris automatically retrieves and analyzes news on your topics of interest every day, so you can quickly scroll through an annotated news feed on your phone, tablet or laptop, while finishing your morning coffee.

Example: A Pluaris enterprise customer was interested in tracking news and events in the telecom industry. Nowigence was able to quickly create and then fine-tune a list of topics to monitor. In less than a week, they had an annotated news feed covering the telecom industry available to their team.

I have to come up to speed on a new topic as quickly as possible. Upload a few related websites and documents to Pluaris and within minutes you are exploring this new area of interest, scanning the summaries, gaining new insights about this topic, and finding new keywords to broaden your search and deepen your understanding.

Example: A customer who was already using Pluaris for business intelligence decided to use his account to make improvements in his health after he received a report from his doctor of a high fasting blood sugar level.

  • He uploaded a few research reports to Pluaris, read through the summaries, and explored the annotated labels. Based on that analysis, he set up Pluaris to monitor topics such as “lowering fasting blood sugar” and “low glycemic food.”
  • From those results, he built an action list of daily habits for diet and fitness and, within a couple months, brought his fasting blood sugar level back down.

I want to be able to access the information I’ve read in the past and synthesize it with my current understanding. As you continue to add more and more information to the system over time, Pluaris never forgets. You are building a knowledge base of the information that is most relevant to you.

Example: A Pluaris user at one of the world’s largest aluminum mining companies was tasked with preparing talking points for her manager for an upcoming investor meeting. Over time using Pluaris, she had built a database of documents, including transcripts, notes, Q&A sessions, speeches, annual reports, and internal documents, some of which were from previous investor meetings. She was able to quickly explore that database through the Pluaris Dashboard and using various filters. She then pulled this information together in a Pluaris Notebook and shared that note directly with her boss.

Market Outlook

Pluaris users include:

  • Knowledge WorkersGartner estimates there are more than 1 billion worldwide as of December 2019.
  • Students in Higher Education: ICEF estimates there are 250 million worldwide as of 2020. This is Nowigence’s initial target group from a market penetration perspective.
  • Personal/Home Use: Statista estimates there are 4.7 billion active internet users worldwide as of January 2021.

Nowigence offers tiered pricing, starting at $10/month/user for individuals, while team and enterprise users, who have access to more features to facilitate collaboration and integrations to other enterprise tools, start at $45/month/user.

As a result, the Total Available Market (TAM) is more than a billion users and over $1 trillion. The Market Opportunity (the Serviceable Obtainable Market or SOM) for Nowigence is $11 billion in the combined PKM and Cognitive Computing space defined by Pluaris.

This market is growing rapidly too. The Cognitive Computing market alone was valued at $8.87 billion in 2018 and is projected to reach a value of $87.39 billion by 2026, growing at a CAGR of 31.6% from 2019 to 2026, according to Allied Market Research.

Nowigence offers differentiated value compared to other Personal Knowledge Management (PKM) tools, which have reached as many as 250 million users (Evernote) and have shown rapid adoption (Roam Research reached 60,000 users and $1 million ARR within 6 weeks of launching paid plans). Unlike Pluaris, these tools do not automatically monitor public or private sources to add to your knowledge base, nor do they provide summaries or extract intelligence. Pluaris differs from search engines as well, in that search engines do not access or store personal knowledge, and they also do not summarize or extract intelligence.

Management Team

Anoop Bhatia is the founder and CEO of Nowigence Inc., where he has worked full-time since 2015. Previously, he worked as a global operation strategic transformation leader for Momentive Performance Material (formerly GE Silicones). He has worked for over two decades in various General Electric companies across different countries, including the U.S., India, The Netherlands and Germany. He played a key role in establishing GE Silicones as the first-ever wholly owned foreign subsidiary established in India in 1996. He received his Bachelor of Engineering in Chemical Engineering from BITS in India and did his post-graduate studies in management from Heriot-Watt at Edinburgh in Scotland.

Gordon Haupt is the Chief Technology Officer at Nowigence. He has more than 20 years of experience building and leading diverse engineering and operations teams, and a strong technical background in machine learning, signal processing, and statistical data analysis, including applications in speech and text, biotechnology, and computer vision. He is a named inventor on 15 issued patents and is experienced in all phases of engineering development and operations. He holds a B.S. degree in Engineering Mechanics from the University of Wisconsin and M.S. and Ph.D. degrees from Stanford University in Aeronautics and Astronautics.

David Evans is the company’s acting CFO & General Counsel. As an attorney and licensed CPA in the state of New York, he has extensive experience in multistate and international tax policies and guidelines, federal taxation laws, mergers and acquisitions, including valuation of closely held businesses. He is a contributing author to the New York State Tax Service, a six-volume publication of NYS tax laws and regulations. His prior experience includes being a Managing Director for UHY Advisors LLC, a board member and chairperson of the Tax Division Executive Committee of New York State Society of Certified Public Accountants and a past president of the Estate Planning Council of Eastern New York. He holds degrees from Hofstra University and State University of New York at Buffalo.


Recent News

chart

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

  • Lexaria began its human clinical study on oral nicotine alternatives, evaluating the effectiveness of its DehydraTECH-nicotine pouch performance
  • Earlier in the year, the company also announced the commencement of its HYPER-H21-4 human clinical study on the effectiveness of DehydraTECH-processed CBD for hypertension treatment
  • Lexaria has also made some significant progress in the use of its technology for the enhanced delivery of antiviral drugs
  • It hopes that before the end of 2022, it will have built sufficient data to effect meaningful industry progress and sustainable increases in valuation

Lexaria Bioscience (NASDAQ: LEXX), since its inception, has been pushing the boundaries of drug delivery. Through its patented technology, DehydraTECH(TM), the company has achieved more efficient delivery of active pharmaceutical ingredients into the bloodstream while also increasing their bioavailability.

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules.  DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Wednesday's trading session at $2.37, off by 4.4355%, on 58,859 volume. The average volume for the last 3 months is 58,859 and the stock's 52-week low/high is $2.308/$12.50.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced that its Vessel brand, a leader in premium cannabis accessories, secured meaningful penetration in Canada via an approved listing on the Ontario Cannabis Store (“OCS”). In addition, Vessel has launched its Canadian direct-to-consumer online store, www.VesselBrand.ca, to service customers directly across the country. “We’re elated about our partnership with the OCS and are looking forward to bringing the full Vessel experience to our loyal customers across Canada,” said Flora’s Chief Strategy Officer James Choe. “Our internal estimates show the Canadian cannabis market will be around CAD 5.9 billion this year, with the ancillary category making up about $350 - $475 million. That market potential, coupled with our expectations around meaningful retail door penetration across the country, signals promising growth in this market.” To view the full press release, visit https://ibn.fm/lQaMq

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Wednesday's trading session at $1.18, off by 9.2308%, on 661,332 volume. The average volume for the last 3 months is 659,644 and the stock's 52-week low/high is $1.17/$21.45.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its CEO Doug Drysdale will participate in a fireside chat at the H.C. Wainwright Global Investment Hybrid Conference. The event is taking place May 23-26, 2022, at the Fontainebleau Miami Beach. Drysdale’s fireside chat will be webcast live at 12:30 p.m. ET on Wednesday, May 25. Interested parties should visit https://ibn.fm/0nlvQ to register and access the live webcast. An archived version of the webcast will also be available on the company’s investor relations website. To view the full press release, visit https://ibn.fm/FBIJj. A new study has found that individuals are cautious about the use of psilocybin-assisted psychotherapy in the treatment of depression. Psilocybin is an active chemical found in magic mushrooms. This mind-altering compound may influence how individuals experience the world by inducing changes in the sense of self as well as a user’s perception of time, sensory perception and mood. Preliminary studies have shown that administering psilocybin in conjunction with psychotherapy can bring about improvements for patients afflicted by depression. As more companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) conduct research on psilocybin and other hallucinogenic compounds, more information will become available to the public, and the confidence to opt for these new medicines will grow.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Wednesday's trading session at $0.41, off by 15.4813%, on 951,258 volume. The average volume for the last 3 months is 916,854 and the stock's 52-week low/high is $0.41/$3.38.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

  • CNS Pharmaceuticals is developing a proprietary drug candidate that has the potential to deliver a novel solution for unmet medical needs in treating an incurable brain cancer
  • CNS’s drug candidate is called Berubicin, a powerful anthracycline that appears to be the first such chemotherapy agent able to successfully cross the blood-brain barrier
  • Berubicin dosing has begun in a potentially pivotal global trial that is recruiting glioblastoma multiforme (“GBM”) brain cancer patients
  • The FDA has granted CNS fast-track authorization in regard to Berubicin’s development, and European countries’ drug regulatory bodies are also granting authorization to advance the trial process there
  • An April 14 Virtual Investor Spotlight Event provided investors with information on CNS’s efforts, and the Zoom webcast will remain viewable through July for interested parties

Investors interested in potentially getting on board with a biopharmaceutical company working to develop novel brain cancer solutions can learn about the unmet need for treating deadly glioblastoma (“GBM”) and the work CNS Pharmaceuticals (NASDAQ: CNSP) is putting into granting GBM patients new hope by reviewing a recent Virtual Investor Spotlight Event that will be viewable for the next few weeks. When cancer cells spread to the brain, they lead to the formation of brain metastases. Metastases are the primary cause of mortality and morbidity linked to cancer. Researchers at Instituto de Medicina Molecular have developed models to study brain metastases, which may help to better understand cancer and find new treatment approaches that can be modified to fit the needs of every patient. For their study, the researchers gathered brain metastases from patients with cancer that arose from tumors located in other organs. They used these cells to generate ailment models that mimicked the illness of every patient. This additional information discovered about the ways through which cancer metastasizes adds to the pool of knowledge made available by entities such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) as they conduct R&D on cancers affecting the brain.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday's trading session at $0.2754, off by 8.2%, on 382,556 volume. The average volume for the last 3 months is 382,556 and the stock's 52-week low/high is $0.2453/$2.68.

Recent News

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF)

The QualityStocks Daily Newsletter would like to spotlight Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF).

Eat Well Group (CSE: EWG) (OTC: EWGFF), a publicly traded investment company, has announced that Amara Organic Foods, one of its investee companies, has been named no. 5 on Business Insider’s fastest-growing direct-to-consumer brands. In addition to that, Amara also earned a spot on Good Housekeeping’s list of best organic baby foods for 2022. The Business Insider ranking was based on Similarweb data, including monthly traffic and Q1 growth across several different categories, such as food, personal care, and health. According to the announcement, Amara’s average monthly website visits reached visits almost 40,000 with quarter-over-quarter web-traffic growth of 286%. The Good Housekeeping distinction was determined by a panel of children, parents and GH editors, which tested several different brands to determine which products are the best for babies. “To be considered one of the fastest growing D2C brands is a tremendous honor and validates what our entire team at Amara continues to build; our goal remains to become a household name in infant nutrition,” said Amara CEO and founder Jessica Sturzenegger in the press release. “More and more parents and families are looking for healthier, more nutritious and affordable plant-based foods for their babies and toddlers. We are continuing to expand our distribution channels and will drive step changes in 2022 and beyond.” To view the full press release, visit https://ibn.fm/1xALh

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF), headquartered in Vancouver, British Columbia, is a publicly traded vertically integrated plant-based foods company combining the best of agribusiness, foodtech, and CPG brands to supply the world with innovative, delicious, and better-for-you foods. The company supplies Beyond Meat, Ingredion, Nestle, General Mills and more. It is on track to generate $60 million in revenue for 2021 and is projecting $100 million in revenue for 2022.

Eat Well’s management team has an extensive record of sourcing, financing and building successful companies across a broad range of industries and maintains a current investment mandate on the health and wellness industry. The team has financed and invested in early-stage venture companies for more than 25 years, resulting in the ability to construct a portfolio of opportunistic investments intended to generate superior risk-adjusted returns. Eat Well’s strategic advisory board includes pioneers in the plant-based foods industry, including HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, and Jeff Dunn, CEO of Bolthouse Farms who previously held senior leadership positions at both Campbell Soup Company and The Coca Cola Company.

The company’s plant-based investment thesis is centered on growing its seed-to-market operations, which include raw ingredients, processing, pulse fractionation, unique IP and premium consumer packaged goods (CPG). Eat Well Group is building a unique ecosystem that can supply these essential cornerstone needs for society. The company has plant-based foods and nutrition experts specializing in the latest science and original thinking for what consumers want most – high quality and affordability in healthy, clean and simple products.

Eat Well focuses on intellectual property, product portfolio development and long-term value creation for stakeholders in a rapidly expanding industry. As an emergent sector globally, plant-based foods represent a double-digit annual growth category, with more than 35% of the world’s supply of pulse proteins coming from Canada.

Portfolio

On July 31, 2021, Eat Well Group acquired Belle Pulses Ltd., one of the top pulse processors in Canada. Belle Pulses has been operating for over 40 years and had over $60 million in sales in 2020. The company counts a broad range of customers in over 35 countries, including global strategic food companies and major ingredient distributors. Currently, Belle produces nearly 100,000 tons of fully traceable seed and product, yielding over 26,000 tons of pure plant protein.

Eat Well also owns 100% of Sapientia Technology Inc. Led by Dr. Eugenio Bortone – one of the world’s preeminent food scientists and extrusion processing experts and the inventor of Frito-Lay’s Twisted Cheetos – Sapientia has filed four patents around the “protein curl” and crispy-puff-style snack. By focusing on texture and crunch, Sapientia’s patents solve one of the major problems that large scale snack food companies have struggled with for years – how to offer appealing texture and flavor in a guilt-free, not fried, natural and healthy alternative to the majority of snack food products available today.

Eat Well owns a 51% share of Amara Organic Foods, with an option to acquire additional ownership up to 80 percent. Amara, one of the fastest-growing baby food brands in America, is a food technology company that uses science and proprietary IP that locks in taste and texture to make healthy, organic, non-GMO, plant-based, convenient baby and children’s food possible for modern-day families. From baby food to toddler food and beyond, Amara is driven by the belief that setting kids on the right path from a young age will help them live better, feel better and think better for the rest of their lives. Amara’s revenues have grown by more than 400% since January 2021, and the brand’s success has drawn media coverage from business news outlets including Forbes and TechCrunch.

Market Outlook

According to an August 2021 report from Bloomberg Intelligence, the plant-based foods market is expected to experience explosive growth, comprising up to 7.7% of the global protein market by 2030 at a value of over $162 billion, up from $29.4 billion in 2020. Bloomberg notes that plant-based alternatives are here to stay, and that consumption will grow rapidly. Plant-based food sales in 2020 grew twice as fast as overall food sales, according to Polaris Market Research.

Pulse proteins (fava, yellow pea, etc.) are a foundational ingredient to most plant-based foods due to their high protein content and their readily available, affordable supply.

Many analysts view the food tech market as similar to the early days of the Internet in that plant-based foods represent a worldwide secular trend of steady growth and potential that will revolutionize the way society functions and people experience nutrition.

The sector continues to experience significant M&A transactions. Recently, Sol Cuisine was acquired by PlantPlus Foods LLC, a major South American protein producer, in an all-cash transaction valued at approximately $126 million, or 6x revenue.

Management Team

Marc Aneed is President and Director of Eat Well Group. His 20-year career in CPG started at The Quaker Oats Company/PepsiCo, where he worked on iconic brands like Gatorade. He previously was at Glanbia PLC, a global nutrition company, where he led Amazing Grass, a leading plant nutrition and supplement company with over $100 million in retail sales. He also led Glanbia’s Sports Nutrition brands in North America with over $750 million in retail sales. Mr. Aneed has launched dozens of successful consumer products, driving over $1 billion in collective retail sales.

Mark Coles is the company’s Chief Investment Officer. He is a veteran CPG senior executive specializing in the plant-based foods sector. For the past decade, Mr. Coles has spearheaded global plant-based start-up initiatives, culminating in a 2020 acquisition by an international New York Stock Exchange-listed food ingredient company. He has over 25 years of experience in CPG-focused strategy, mergers and acquisitions and project financing.

Patrick Dunn is Eat Well Group’s Vice President, Finance. He is the founding partner of Dunn, Pariser & Peyrot and has a track record of building highly successful agribusinesses throughout North America and other international markets. As a testimony to his business portfolio work, Mr. Dunn and his firm have won multiple industry awards for accounting, finance and business management.

Barry Didato is the company’s Vice President, Strategy. He is focused on the development of strategic revenue channels, sales partnerships, and international distribution for Eat Well Group. Mr. Didato brings extensive strategic sales capabilities and an extensive network of contacts in the industry to the company. Prior to joining Eat Well Group, he served for over 18 years as a senior advisor for several ultra-high net worth family offices and numerous innovative wellness, nutrition, medical, and food businesses.

Strategic Advisory Board

HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, is a firm supporter of clean energy and the humane treatment of animals. He is also a vocal supporter of the private sector in the Middle East. A member of the Saudi Arabian Royal Family, Prince Khaled was born in Stanford and spent his youth in Riyadh under the mentorship of his father, philanthropist HRH Prince Alwaleed bin Talal Al Saud, Chairman of Kingdom Holding Company. He is also the Founding Chairman of KBW Investments and serves across several boards. He invests in an array of successful but diverse global businesses – from promising technology startups to established companies. Today, with holdings on three continents, Prince Khaled stands at the gateway between the Middle East’s evolving economies and the Western world. Consistently, Prince Khaled’s focus is on ventures and ideas at the intersection of innovation and economic growth.

Jeff Dunn has over 30 years of experience in agriculture and packaged food, including senior leadership positions with Bolthouse Farms, Campbell Soup Company and The Coca Cola Company, among others. He is an Operating Partner at Butterfly and focuses primarily on the agriculture & aquaculture and food & beverage product sectors. Prior to joining Butterfly, Mr. Dunn was the President of the Campbell Fresh division of Campbell Soup Company from 2015 to 2016, where he was in charge of building Campbell’s scale and accelerating its growth in the rapidly expanding packaged fresh segments and categories across the retail perimeter.

Eat Well Investment Group Inc. (OTC: EWGFF), closed Wednesday's trading session at $0.19, off by 11.9555%, on 79,900 volume. The average volume for the last 3 months is 79,900 and the stock's 52-week low/high is $0.186/$1.00.

Recent News

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF)

The QualityStocks Daily Newsletter would like to spotlight Red White & Bloom Brands Inc. (OTCQX: RWBYF).

Red White & Bloom (CSE: RWB) (OTCQX: RWBYF) has been strengthening its revenue streams in the states where it operates, particularly in Michigan, Florida and California of late, while also working to deal with its debt to make it more long-term feasible, announcing recently that it has eliminated several million dollars’ worth of liabilities and annual expenses. “The acquisition earlier this year of a 15,000-square-foot manufacturing, processing and distribution facility as well as properties owned by PharmaCo Inc., in Michigan, plus full licensing for manufacturing both medical and adult-use cannabis products in the state, assured RWB’s efforts to become fully vertically integrated and to expand the reach of Platinum Vape,” notes a recent article. In an April 20 announcement, RWB noted its intention to “eliminate an intangible asset of about $77 million as well as a license liability of $60 million from its balance sheets following restructuring of its debt while reducing ‘well over $100 million of liabilities without any dilution to our shareholders,’ a continuation of efforts since last year to cut debt.” Of the strides RWB has achieved, the recent article quotes CEO Brad Rogers as saying, “We are very pleased with the significant balance sheet and operational improvements we have made in a relatively short period of time.” To view the full article, visit https://cnw.fm/S7E1L

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) is a torchbearer blazing a new frontier in American cannabis by adhering to the highest ethical, manufacturing, educational, branding and employment standards available in the industry.

Red White & Bloom is a super state operator, leveraging a sizable footprint to dominate the areas in which it operates. CEO Brad Rogers and other management members have seen the struggles of multi-state operators who have spread themselves too thin, which is why Red White & Bloom is intent on dominating each state it enters before expanding further.

Although targeting individual states in the United States, the company is headquartered in Toronto, Canada. Red White & Bloom was established after privately held MichiCann Medical Inc. merged with publicly traded Tidal Royalty in 2019.

Brands

Red White & Bloom has entered strategic brand acquisitions and partnerships aimed at helping the company expand its presence and position as one of the largest players in the United States cannabis market. Red White & Bloom is always diligently searching for brands to acquire that will provide additional value to the company and expand its national footprint.

The company’s current brand portfolio includes:

  • Platinum Premium Cannabis Products (PV): Platinum uses innovative thinking, honesty and responsibility to remain at the forefront of the cannabis industry. PV holds itself and its partners to the highest standards, providing clean and safe CBD and THC products. In the company’s press release dated January 13, 2021, it reported system-wide sales of Platinum-branded products exceeding $2.8 million for the first week of January alone.
  • High Times®: In June 2020, the company acquired the licensing rights and branding of High Times dispensaries and High Times cannabis-based CBD and THC products in Michigan, Illinois and Florida. The company also acquired branding of High Times hemp derived CBD products nationally in the United States carrying the Culture® brand.
  • Mid-American Growers: Mid-American began as a family operation in 1971 in Granville, Illinois. The original 8-acre greenhouse has expanded to a 3.6-million-square-foot, state-of-the-art technology and science facility under glass. Mid-American’s product offerings include its CBD Icy Relief Salve, CBD Icy Relief Roll-on and CBD Gummies.

Retail Focus

Red White & Bloom is working to establish a significant retail presence across multiple jurisdictions. In Michigan, the company is invested in and has the rights to acquire (subject to regulatory approvals) a licensed operator that controls the assets of 18 dispensary locations throughout the state. Red White & Bloom is also pursuing opportunities in Florida aimed at making its proposed retail footprint compelling and attractive to the majority of cannabis consumers within each state.

Cultivation

Red White & Bloom is focused on standardization and quality, with everything guided by a relentless commitment to the highest standards. The company acquired a 3.6-million-square-foot standardized facility dedicated to helping it achieve premium value for the products it intends to cultivate.

As it continues to expand, the company remains committed to the practices that have guided its success in the past, including:

  • A top-down approach to cultivation developed under the guidance of PhDs with expertise in growing principles, SOPs and, most importantly, the science behind it all.
  • Commitment to exceeding the requirement of the states in which it operates. The company cut its teeth under the world’s first national cannabis purity regime – a regime that most new markets use as a benchmark – so quality is in its DNA.
  • Science-driven production methods supported by automated, perpetual, standardized operations that enable craft cannabis-like quality at an industrial scale.

Footprint

Assuming completion of the currently proposed investments and acquisitions, Red White & Bloom will be among the cannabis market’s largest companies, joining the ranks of a select few multi-state operators dominating the industry. Red White & Bloom currently has assets (closed and in closing stages) in Michigan, Illinois, Florida, California, Oklahoma and Massachusetts.

The company’s strategic acquisition and super state operator model, combined with its commitment to top-quality product and service, position it to become a leading player in the North American cannabis market.

When evaluated beside competitors in the cannabis space, Red White & Bloom boasts an extremely attractive valuation. While large cap cannabis firms serving North American markets averaged enterprise-value-to-EBITDA multiples of 14.9x as of December 2020, Red White & Bloom’s enterprise multiple was just 3.4x, as noted in the company’s latest investor deck.

In 2020, the cannabis market worldwide was valued at $24.6 billion. This amount is expected to expand at a CAGR of 14.3% from 2021 to 2028, resulting in a market size of $84 billion in 2028 (https://nnw.fm/f09ZL). Of the 2020 valuation, the largest revenue share (91.1%) was attributed to North American consumers (https://nnw.fm/vObW6).

Management Team

Brad Rogers is the CEO and Executive Chair of Red White & Bloom. He is a visionary for the future of cannabis and CBD products in the United States market, with a proven track record of building successful and profitable businesses in the rapidly expanding and new economic sector. Mr. Rogers was a part of the team that built one of the first commercially scaled production facilities in the world for medicinal cannabis. He also served as President for one of the leading licensed producers in Canada. Both of his ventures were successful, with a combined market cap of $2 billion.

Michael Marchese is the company’s Co-Founder and Marketing Advisor. He has played a crucial role in its development and organization, overseeing capital raises, acquisition strategy and brand identity. Mr. Marchese has a strong reputation and presence in the cannabis industry. He also co-founded and directed the branding of Aleafia Health Inc., which he continues to counsel. Through his branded company, Marchese Design, he has served as a highly trusted counselor to top-level execs, including C-Suite level employees, offering insights into the process of creating, building and maintaining brand identities.

Theo van der Linde is the CFO and Director of Red White & Bloom. He is a Chartered Accountant with 20 years of experience in finance, administration and public accounting. The experience he has acquired spans multiple industries, including mining, oil & gas, financial services, retail and manufacturing. For the last nine years, he has primarily focused his career on the mining industry, working with junior exploration and producing mining companies at various stages of growth in several jurisdictions. Mr. van der Linde is also the current President of Executive Management Solutions Ltd.

Red White & Bloom Brands Inc. (RWBYF), closed Wednesday's trading session at $0.1683, off by 1.8888%, on 45,641 volume. The average volume for the last 3 months is 45,641 and the stock's 52-week low/high is $0.157/$1.21.

Recent News

Kronos Advanced Technologies Inc. (OTC: KNOS)

The QualityStocks Daily Newsletter would like to spotlight Kronos Advanced Technologies Inc. (OTC: KNOS).

Kronos Advanced Technologies (OTC: KNOS) is the exclusive national distributor of a revolutionary new air-purification device engineered for personal space protection. “The ViralWall(TM) is designed to be placed between individuals, draw in their exhaled air, kill or disable pathogens as they move through the patented graphene-based air filter, and then release disinfected pathogen-free air. The first-ever self-sterilizing graphene air purifier on the market, the ViralWall was developed by Israel-based R&D company LIGC Application Limited… ‘The graphene air filters will be more efficient, cost-effective, consume less energy, and require far less maintenance than other air filters currently on the market,’ said Kronos CEO Michael Rubinov,” a recent article reads. “Becoming the exclusive national distributor of this innovative device aligns with the focus of Kronos Advanced Technologies, a company committed to changing the way indoor air is filtered and disinfected… KNOS is eyeing the growing [global graphene] market as it looks to develop and support disruptive manufacturing methods and graphene-based futuristic products today. Its distribution agreement with LIGC supports that strategy… KNOS anticipates making many LIGC offerings at its electronics manufacturing facility in West Virginia.” To view the full press release, visit https://ibn.fm/q8jdX

Kronos Advanced Technologies Inc. (OTC: KNOS) develops and sells a variety of disruptive, advanced, state-of-the-art air filtration and purification systems that fully remove harmful allergens, bacteria, viruses (including the flu), and even gasses from indoor breathing spaces, including healthcare and other settings.

Kronos’ own patented medical-grade technology is tested as the most effective clean air solution on the market. Kronos filters particles down to .0146 micron (.0146μm) – far beyond the 3 microns (0.3μm) of a traditional HEPA filter. Kronos® not only collects but destroys air pollutants. Kronos® AIR 5G® Air Purifiers use about 30,000 volts inside to actively destroy 99.99% of all airborne bacteria, mold, and virus particles.

Kronos® devices operate silently using nanotechnology to remove 100% of pollutants in a 400ft2 room (up to the whole house) and replenishes the room with pure, clean air every 15 minutes. Indoor household air is often four times more polluted than outdoor air, and Kronos air purifiers act like bionic lungs for the home and protect the people in it.

Unlike traditional HEPA systems that collect pollutants on filters which can, over time, grow mold and bacteria, Kronos’ patented technology destroys and eliminates all manner of harmful particles and deposits them on easy-to-clean collecting plates. This reduces the risk of harmful particles in the air and eliminates the need to replace costly HEPA filters every month.

The Kronos® AIR 5G® Air Purifier destroys and eliminates dust, allergens, bacteria, and even viruses. The AIR 5G® has been third party lab tested and confirmed to kill 99.87% of influenza virus in one hour.

The patented system’s five step process starts with a pre-filter screen that filters and collects hair, pet dander, etc. The air is then pulled through emitter wires which create a 30,000-volt electro field that zaps dangerous particulates. In the ionic field, charged particles are destroyed, killing bacteria and pathogens. The particles are then captured on collecting plates, removing dangerous toxins from circulation. The collecting plate is easily cleaned and reused without buying new filters. The catalytic layer is the final step in the purification process, removing odors and keeping the air fresh and pure. The AIR 5G® has Smart Control Auto Mode, which measures and displays the air quality in the room and self-adjusts fan speed based on how dirty the air is in the room. There’s also an AIR 5G® Smart App that displays the real time Air Quality Index and acts as a remote control.

The Kronos® AIR 5G® Air Purifier is offered in three models:

  • Kronos® AIR 5G® X3 air purifier combines powerful patented TPA® technology with a compact form factor up to six times smaller than other air purifiers, with washable and reusable filters.
  • Kronos® AIR 5G® X5 thoroughly wipes out dust, smoke, dander, bacteria, pollen, viruses, odors, germs, and more from the air, delivering the healthiest breathable air possible. It was developed for some of the world’s most polluted areas and is now available for use in the home. It runs completely silently, passing through five stages of purification to guarantee the cleanest possible air in homes or offices.
  • Kronos® AIR 5G® X8 delivers maximum power, more than doubling the capacity and efficiency of the Kronos X5, with CADR speeds of up to 470 CFM – enough to clean a 1,000ft2 room in just 20 minutes.

Kronos also offers the Kronos Car Air Purifier, the most advanced car air purifier with Kronos’ patented TPA® technology, and FitAir, the best personal air purifying solution that brings clean air anywhere by cleaning within 25ft2 of personal space at an airflow rate of 3x per hour.

Market Overview

The global air purifier market was valued at $10.38 billion in 2020 and is expected to reach $21.15 billion by 2027, achieving a CAGR of 10.7% over the forecast period, according to Brandessence Market Research. The market is primarily driven by the increasing concerns about both outdoor and indoor air pollution, coupled with the associated health problems.

Air pollution is one of the most prevalent concerns, due to worsening environmental condition. According to Health Effect Institute, it accounts for 4.9 million to 8.8 million deaths worldwide each year. Furthermore, as most of our time is spent is indoors, indoor air pollution remains a serious concern to individuals, as well as regulatory agencies. Particles like PM 2.5 can enter indoors through a wide range of sources including car engines, fireplaces, and coal- or natural gas and the infiltration of ambient particulates in urban areas. Even in the absence of solid fuels, indoor ventilation can build up PM 2.5 particles to a greater extent than in outdoor environments. Growing demand for portable air purification filters and systems in urban areas, increased advancements to catch key particulates like coronavirus, and increased regulatory measures to ensure safe environments for professionals in the industrial sector remain leading drivers of growth in the air purifier market.

Poor indoor air quality can cause fatigue, headache, and irritation of the eyes, throat, lungs, and nose, which can have a negative impact on worker productivity. Some air contaminants can cause asthma and other respiratory diseases.

Air purifier adoption is increasing rapidly in the U.S. to minimize health issues caused by poor air quality. Strict air quality standards, guidelines, and regulations in the U.S. are expected to have a positive impact on the market. For instance, the New Jersey Indoor Air Quality standard, NJAC 12:100-13 (2007), sets guidelines and standards related to indoor air quality during working hours in public employee-occupied buildings.

Key manufacturers are focusing on acquisitions and mergers to expand their geographical reach and strengthen their position in the market.

Management Team

Michael Rubinov, President and Head of Business Development

A seasoned hi-tech executive with 25 years of global business experience, Mr. Rubinov has served in various positions in sales, marketing, channel development and partner management. He has worked for large and global organizations such as Intel, NICE Systems, and Boeing (Defense and Security), as well as for start-up companies like Dialogic and Remunera International SA. He was appointed President and Head of Business Development of Kronos Advanced Technologies Inc. in February 2020. Mr. Rubinov holds an MBA, an MS Computer Sciences, and a BS Electrical Engineering.

Joseph L. Florence, Chief Operational Officer & CTO

A dynamic skilled leader in all aspects of business formation, evaluation, and execution, Mr. Florence brings a unique combination of Fortune 100 company experience with a lifetime of entrepreneurial experience to the Kronos team. He is a gifted visionary, possessing the unique ability to see future opportunities and make timely strategic adjustments and is naturally gifted at seeing unrecognized risk and overlooked opportunities. Mr. Florence has a proven track record of transforming companies to better align people, processes, and technologies to meet strategic goals and business metrics resulting in increased market share and profitability.

Kronos Advanced Technologies Inc. (OTC: KNOS), closed Wednesday's trading session at $0.011, off by 7.9498%, on 154,258 volume. The average volume for the last 3 months is 154,258 and the stock's 52-week low/high is $0.01/$0.0785.

Recent News

Friendable Inc. (FDBL)

The QualityStocks Daily Newsletter would like to spotlight Friendable Inc. (FDBL).

  • Fan Pass Live with Artist Republik and FeaturedX is creating a 360 platform with pricing that sets them apart from competitors
  • The May contest on Instagram is underway, and features Grow with Us (“GWU”) campaigns to help artists build their fanbase on Spotify/Soundcloud
  • In the first 100 days, positive growth has been reflected across revenue per subscriber, spend per customer, and subscriber lifetime value
  • Key metrics for social media have also seen an increase across the board

In the five months since announcing the acquisition of Artist Republik (and FeaturedX), Friendable (OTC: FDBL), and its flagship offering, Fan Pass Live artist platform, has seen increased growth in several areas, including social media reach, artist recruitment, and fan subscriptions – among other metrics. The combination of services has provided Friendable with the first 360 artist platform offering, resulting in a one-of-a-kind “anti-label” movement.

Friendable Inc. (FDBL) is a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications. Launched July 24, 2020, the company’s flagship offering is designed to help artists engage with their fans around the world and earn revenue while doing so. The livestreaming platform supports artists at all levels, providing exclusive artist content ‘Channels’, LIVE event streaming, promotional support, fan subscriptions and custom merchandise designs, all of which serve as revenue streams for each artist.

With Fan Pass, artists can offer exclusive content channels to their fans, who can use their smartphones to gain access to their favorite artists, as well as an all-access pass to all artists on the platform. Additionally, the Fan Pass team will deploy social broadcasters to capture exclusive VIP experiences, interviews and behind-the-scenes content featuring their favorite artists – all available to fan subscribers on a free trial basis. Subscriptions are billed monthly at $3.99, or about the cost of downloading a couple of songs, and VIP experiences are available at a fraction of the cost of traditional face-to-face meetups.

Friendable Inc. was founded by Robert A. Rositano Jr. and Dean Rositano, two brothers with over 27 years of experience working together on technology-related ventures.

The Fan Pass Mobile & Desktop App

Friendable Inc. launched its Fan Pass platform as a solution for artists and their fans as the COVID-19 pandemic and the associated shutdown have continued to severely hamstring the entertainment industry as a whole. Through Fan Pass, the company aims to reach artists at all levels looking to alter their touring schedules to include ‘Virtual Touring’, new revenue sources and innovative fan engagement opportunities that are expected to become permanent fixtures of artists’ touring routines moving forward.

Fan Pass creates an ecosystem that embraces fans of all kinds, feeding diehard followers and developing lasting connections with more casual supporters. Through the app, qualified artists are provided with a custom designed, exclusive ’Fan Pass Channel’ where they can invite fans and social followers from anywhere around the world to join in chats and live events – allowing fans to experience all there is to see of an artist in one place. Artists earn revenue from monthly fan subscribers, merchandise sales, tickets sold for virtual streaming events and generally from all content views or impressions on their channels. All content views and sales of every kind are reported to each artist through their dashboards, including real-time payout and earnings information.

Fan Pass’ exclusive ‘All Access VIP’ option provides fans with access to content, such as:

  • Live performances or online concerts
  • Backstage meetups before, during or after events
  • Livestreams of studio sessions
  • Behind-the-scenes footage of music video and photo shoots
  • Special interviews and one-on-one videos
  • Streams highlighting the artists’ daily lives

The Fan Pass platform is extremely intuitive, bringing each artist through a streamlined onboarding process, including building out artist ‘Channels’, scheduling LIVE events and designing special edition merchandise to be offered solely through exclusive Fan Pass merchandise stores.

“With the global pandemic disrupting the entertainment industry in such a profound way, artists have had to look to digital distribution and live virtual performances in order to maintain any earning opportunities. Fan Pass and our team are determined to provide solutions and support to all artists, their fans and the industry in general. We are excited about the opportunity we have to shape the future of virtual entertainment, revenue generation and artist/fan engagement,” Robert A. Rositano Jr., CEO of Friendable Inc., stated in a news release.

Market Opportunity

Artists rely heavily on revenue streams that are not often seen by those without intimate industry knowledge. When it comes to traditional performances, the sale of VIP/backstage or meet & greet passes to boost revenue can often become the majority of the artist’s annual tour revenue. Data provided by one of the company’s original entertainment partners, The Kluger Agency (TKA), suggests that as much as 18-23% of artists’ annual tour revenue has historically been derived from these VIP experiences.

The World Economic Forum reports that, in 2020, the six-month-plus disappearance of live music concerts is estimated to have cost “the industry more than $10 billion in sponsorships,” and individual artists are feeling the loss the most. Fan Pass is helping to bridge this gap, providing more affordable virtual VIP experiences that can be offered simultaneously to fans around the world.

While it’s free for artists to join, Fan Pass leverages a monthly subscription model paid by fans to generate revenues. These revenues are shared with all channel artists. In exchange for its platform features, live streaming tools, bandwidth, processing and handling, Fan Pass earns platform fees on each separately ticketed event, as well as splits with each artist on subscriber fees and merchandise designed and sold on the platform.

The U.S. video streaming industry is expected to hit $7.08 billion in value in 2021, with an estimated 100 million internet users watching online video content every day, according to data from Livestream.com. The same report suggests that 45% of live video audiences would pay for exclusive, on-demand video from a favorite team, speaker or performer. Through Fan Pass, Friendable Inc. is uniquely positioned to capitalize on this opportunity.

Friendable App

The company’s second application, Friendable, is an all-inclusive platform where users can meet, chat and date. The app has exceeded 1.5 million total downloads, with over 900,000 historical registered users and more than 580,000 historical user profiles.

Friendable Inc.’s Next Phase of Growth

To facilitate its next phase of growth, Friendable Inc. is seeking an additional $1 million in equity investment, with a follow-on funding that meets or exceeds $5 million. The company intends to utilize its relationships to secure the lowest cost of capital available, as these funds will drive technology advancements, increase head count, fund marketing initiatives and secure additional celebrity talent aimed at bringing larger fan audiences to each released event. These initiatives will assist in building recurring monthly (fan) subscribers, effectively generating recurring monthly revenue for each artist, as well. The next phase of growth is expected to play a key role in accelerating the company’s download and conversion of data for subscription revenue and merchandise sales.

The company’s primary goal is to establish Fan Pass as a premier brand and mobile platform dedicated to connecting and engaging users around the world. In support of this goal, it has entered into a partnership with Brightcove targeting OTT platform expansion, including leaders such as iOS, Android, Apple TV, Android TV, Roku and WWW.

In the highly competitive video streaming market, Friendable Inc. has tapped into an unmet demand from today’s ever-present ‘omni-users’ for constant contact with celebrities and influencers. Via Fan Pass, the company offers investors an opportunity to gain a stake in an organization catering to this new breed of omni-users and their influencers.

The application’s potential is clearly illustrated by the interest it has generated in recent weeks. From September 4 to October 12, the Fan Pass platform added 246 new artists, accounting for a 410 percent increase in just six weeks.

“We are extremely encouraged by the ongoing swell of interest as the value of our Fan Pass platform continues to resonate in the artist community,” Friendable CEO Robert A. Rositano Jr. stated in a news release. “We believe the live streaming functionality, our full-circle offering and diverse revenue opportunities the platform offers will continue to drive exponential growth as management remains focused on building long-term shareholder value.”

Management Team

Robert A. Rositano Jr. is the co-founder and CEO of Friendable Inc. He oversees the daily management and operational duties of all areas of the business. He has over 20 years of experience as a serial entrepreneur, bringing in over $60 million in liquidity events for the companies he has created or managed. Before starting Friendable Inc. with his brother, Rositano was a founding member of the internet’s first IPO, Netcom Online Communications Inc. It was sold to ICG, then to EarthLink in 1995. He has been a co-founder of several successful ventures, including Simply Internet Inc., Nettaxi.com and America’s Biggest Inc., among others. He also authored one of the first web directories for MacMillan Publishers.

Dean Rositano is the co-founder and Chief Technology Officer of Friendable Inc. He handles the day-to-day operations and guides the technical direction of the company. He has over 15 years of executive management, financial management, high technology operations and internet architecture experience. Before co-founding Friendable Inc., Rositano co-founded several other companies, including Checkmate Mobile Inc. and Latitude Venture Partners LLC, among others.

Friendable Inc. (FDBL), closed Wednesday's trading session at $0.00039, off by 22%, on 68,848,007 volume. The average volume for the last 3 months is 68.848M and the stock's 52-week low/high is $0.00039/$0.0195.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.